Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record.

Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence

Open access
Fackler, Mary Jo, Umbricht, Christopher B., Williams, Danielle, Argani, Pedram, Cruz, Leigh-Ann, Merino, Vanessa F., Teo, Wei Wen, Zhang, Zhe, Huang, Peng, Visvananthan, Kala, Marks, Jeffrey, Ethier, Stephen, Gray, Joe W., Wolff, Antonio C., Cope, Leslie M., Sukumar, Saraswati · 2011 · Cancer Research

Abstract

To better understand the biology of hormone receptor–positive and–negative breast cancer and to identify methylated gene markers of disease progression, we carried out a genome-wide methylation array analysis on 103 primary invasive breast cancers and 21 normal breast samples, using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Estrogen and/or progesterone receptor–positive tumors displayed more hypermethylated loci than estrogen receptor (ER)-negative tumors. However, the hypermethylated loci in ER-negative tumors were clustered closer to the transcriptional start site compared with ER-positive tumors. An ER-classifier set of CpG loci was identified, which independently partitioned primary tumors into ER subtypes. A total of 40 (32 novel and 8 previously known) CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER subtype–specific loci was validated in silico, using an independent, publicly available methylome dataset from the Cancer Genome Atlas. In addition, we identified 100 methylated CpG loci that were significantly associated with disease progression; the majority of these loci were informative particularly in ER-negative breast cancer. Overall, the set was highly enriched in homeobox containing genes. This pilot study shows the robustness of the breast cancer methylome and illustrates its potential to stratify and reveal biological differences between ER subtypes of breast cancer. Furthermore, it defines candidate ER-specific markers and identifies potential markers predictive of outcome within ER subgroups. Cancer Res; 71(19); 6195–207. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-1630

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 201

Metadata

Authors
Fackler, M. J., Umbricht, C. B., Williams, D., Argani, P., Cruz, L.-A., Merino, V. F., Teo, W. W., Zhang, Z., Huang, P., Visvananthan, K., Marks, J., Ethier, S., Gray, J. W., Wolff, A. C., Cope, L. M., & Sukumar, S.
Venue
Cancer Research
Published
2011-09-29
Volume
71
Issue
19
Pages
6195-6207
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2136959508
Cited by
201
References
0
FWCI
7.99
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-1630
The paper
Fackler, M. J., Umbricht, C. B., Williams, D., Argani, P., Cruz, L.-A., Merino, V. F., Teo, W. W., Zhang, Z., Huang, P., Visvananthan, K., Marks, J., Ethier, S., Gray, J. W., Wolff, A. C., Cope, L. M., & Sukumar, S. (2011). Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-1630

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.